Current filters:


Popular Filters

7810 to 7834 of 8849 results

Biotech predictions for 2012 from sector specialist Steven Burrill


As 2011 drew to a close, Steven Burrill, chief executive of global life sciences financial services firm…

BiotechnologyFinancialMergers & AcquisitionsNorth AmericaPharmaceuticalRegulation

Expanded use for Pfizer’s Prevnar 13


Following a previous US Food and Drug Administration advisory panel recommendation (The Pharma Letter…

North AmericaPfizerPharmaceuticalPrevnarRegulationVaccines

Takeda ends Daxas co-promotion with MSD; Actos law suits


Japan’s largest drugmaker, Takeda Pharmaceuticals (TYO: 4502) says that it has reached a mutual…

ActosDaxasDiabetesLegalLicensingMerck & CoNycomedPharmaceuticalRespiratory and PulmonaryTakeda Pharmaceuticals

Knighthood for GlaxoSmithKline’s Andrew Witty; Teva succession plan


Andrew Witty, chief executive of UK drug giant GlaxoSmithKline (LSE: GSK) has been awarded a Knighthood…

GenericsGlaxoSmithKlineManagementPharmaceuticalTeva Pharmaceutical Industries

Turkey’s AiFD highlights pharma industry woes


Turkey’s Association of Research-Based Pharmaceutical Companies (AİFD) has issued a public…


Emergent considers options as Abbott ends drug R&D collaboration


Shares of USA-based Emergent BioSolutions (NYSE: EBS) saw its shares fall 4% to $16.53 after the company…

Abbott LaboratoriesEmergent BioSolutionsLicensingOncologyPharmaceuticalResearch

Alexion to buy Enobia Pharma for potential $1 billion


US drugmaker Alexion Pharmaceuticals (Nasdaq: ALXN) has reached agreement to acquire privately held Canadian…

Alexion Pharmaceuticalsasfotase alfaEnobia PharmaMergers & AcquisitionsPharmaceuticalRare diseases

Apricus Biosciences closes Topotarget USA acquisition


Apricus Biosciences (Nasdaq: APRI) has closed its previously-announced acquisition of Topotarget USA,…

Apricus BioscienceMergers & AcquisitionsOncologyPharmaceuticalTopotargetTotect

Spanish pharma sales down 3.1% in October


Data from Spain’s Ministry of Health, Social Policy and Equality shows that, in October 2011, public…

EuropeGenericsMarkets & MarketingPharmaceuticalPricingResearch

UCB and Immunomedics amend epratuzumab accord


New Jersey, USA-based Immunomedics (Nasdaq: IMMU) and Belgian drugmaker UCB (Euronext Brussels: UCB)…

epratuzumabImmunologicalsImmunomedicsLicensingPharmaceuticalRare diseasesUCB

Australia’s Pharma industry economic impact up by A$1 billion


The Australian pharmaceutical industry’s contribution to the economy grew by an estimated A$1 billion…

Asia-PacificMarkets & MarketingPharmaceuticalResearch

Baxter taps Momenta expertise on biosimilars


In another move to capitalize on the anticipated flood of biosimilars coming to the market, as blockbuster…

Baxter InternationalBiotechnologyGenericsLicensingMomenta PharmaceuticalsResearch

Karo Bio skyrockets on deal with Pfizer


Sweden’s Karo Bio (STO: KARO) saw its shares rocket 80% to 1.67 Swedish ronor on December 24, after…

Anti-Arthritics/RheumaticsImmunologicalsKaro BioLicensingNeurologicalPfizerPharmaceuticalResearch

ViroPharma buys option to acquire Meritage Pharma


ViroPharma (Nasdaq: VPHM) has entered into an exclusive option to acquire fellow USA based Meritage Pharma,…

BudesonideMergers & AcquisitionsMeritage PharmaPharmaceuticalRare diseasesResearchViroPharma

Bristol-Myer’s brivanib disappoints in Ph III study


US drug major Bristol-Myers Squibb (NYSE: BMY) has revealed disappointing results of a Phase III trial…

Bristol-Myers SquibbbrivanibOncologyPharmaceuticalResearch

Eisai re-submits perampanel NDA; FDA accepts Gilead’s Quad


Japanese drug major Eisai (TYO: 4523) says that it has re-submitted the New Drug Application (NDA) for…

Anti-viralsEisaiGilead SciencesNeurologicalperampanelPharmaceuticalQuadRegulation

Exelixis and Sanofi terminate $1 billion cancer deal


US biotechnology firm Exelixis (Nasdaq: EXEL) says its oncology deal with French drug Major Sanofi (Euronext:…


EMA reviewing Novartis aliskiren-containing drugs


The European Medicines Agency is reviewing aliskiren-containing medicines, approved for the treatment…

Aliskiren TabletsCardio-vascularEuropeNovartisPharmaceuticalRasilezRegulationTekturna

Vivus findings show greater risk of birth defects with Qnexa ingredient


USA-based drug developer Vivus (Nasdaq: VVUS) has released top-line preliminary results from its retrospective…

MetabolicsNorth AmericaPharmaceuticalQnexaRegulationResearchtopiramateVivus

Merck gains expanded Isentress indication; lowers price of drug for ADAps


In two pieces of HIV/AIDS-related news for US drugs giant Merck & Co (NYSE: MRK), the company’s…

Anti-viralsIsentressMerck & CoNorth AmericaPharmaceuticalPricingRegulation

Lundbeck divests three branded injectables to Akorn


Danish CNS drug specialist Lundbeck (LUND: DC) says it has entered into an agreement with USA-based niche…

AkornCogentinDiurilGenericsLundbeckMergers & AcquisitionsNembutalNeurologicalNorth AmericaPharmaceutical

7810 to 7834 of 8849 results

Back to top